IL311229A - Triple-agent therapy for cancer treatment - Google Patents
Triple-agent therapy for cancer treatmentInfo
- Publication number
- IL311229A IL311229A IL311229A IL31122924A IL311229A IL 311229 A IL311229 A IL 311229A IL 311229 A IL311229 A IL 311229A IL 31122924 A IL31122924 A IL 31122924A IL 311229 A IL311229 A IL 311229A
- Authority
- IL
- Israel
- Prior art keywords
- cancer treatment
- factor therapy
- therapy
- factor
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163244412P | 2021-09-15 | 2021-09-15 | |
| PCT/US2022/043601 WO2023043883A1 (en) | 2021-09-15 | 2022-09-15 | Triple-agent therapy for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311229A true IL311229A (en) | 2024-05-01 |
Family
ID=85603487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311229A IL311229A (en) | 2021-09-15 | 2022-09-15 | Triple-agent therapy for cancer treatment |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12611411B2 (https=) |
| EP (1) | EP4401720A4 (https=) |
| JP (1) | JP2024531765A (https=) |
| KR (1) | KR20240060625A (https=) |
| CN (1) | CN118159262A (https=) |
| AU (1) | AU2022345084A1 (https=) |
| CA (1) | CA3231639A1 (https=) |
| IL (1) | IL311229A (https=) |
| MX (1) | MX2024003333A (https=) |
| WO (1) | WO2023043883A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2644194T3 (en) * | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| US20100189683A1 (en) | 2008-11-14 | 2010-07-29 | Ascenta Therapeutics, Inc. | Pulsatile Dosing of Gossypol for Treatment of Disease |
| KR101874390B1 (ko) * | 2013-09-26 | 2018-07-04 | 파이브3 제노믹스, 엘엘씨 | 바이러스-연관 종양을 위한 시스템, 방법, 및 조성물 |
-
2022
- 2022-09-15 MX MX2024003333A patent/MX2024003333A/es unknown
- 2022-09-15 US US18/689,980 patent/US12611411B2/en active Active
- 2022-09-15 WO PCT/US2022/043601 patent/WO2023043883A1/en not_active Ceased
- 2022-09-15 EP EP22870665.1A patent/EP4401720A4/en active Pending
- 2022-09-15 CN CN202280069063.5A patent/CN118159262A/zh active Pending
- 2022-09-15 IL IL311229A patent/IL311229A/en unknown
- 2022-09-15 KR KR1020247010862A patent/KR20240060625A/ko active Pending
- 2022-09-15 JP JP2024516808A patent/JP2024531765A/ja active Pending
- 2022-09-15 CA CA3231639A patent/CA3231639A1/en active Pending
- 2022-09-15 AU AU2022345084A patent/AU2022345084A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024531765A (ja) | 2024-08-29 |
| CA3231639A1 (en) | 2023-03-23 |
| EP4401720A4 (en) | 2025-07-30 |
| CN118159262A (zh) | 2024-06-07 |
| MX2024003333A (es) | 2024-05-20 |
| US20250127791A1 (en) | 2025-04-24 |
| WO2023043883A1 (en) | 2023-03-23 |
| US12611411B2 (en) | 2026-04-28 |
| AU2022345084A1 (en) | 2024-03-28 |
| EP4401720A1 (en) | 2024-07-24 |
| KR20240060625A (ko) | 2024-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280707A (en) | Diagnostic and therapeutic methods for the treatment of breast cancer | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| DK4225297T3 (da) | Kombinationsbehandling til behandling af cancer | |
| DK3768830T5 (da) | Cancerterapi | |
| IL270697A (en) | Therapeutic apoptotic cells for cancer therapy | |
| IL307964A (en) | Combined treatment for cancer | |
| IT201900016760A1 (it) | Dispositivo per il trattamento radioterapico di malati oncologici | |
| IL281439A (en) | Combined treatment for blood cancer | |
| EP4190173C0 (en) | METABOLIC THERAPY FOR CANCER | |
| EP4440623A4 (en) | Polytherapy for the treatment of cancer | |
| EP4205812C0 (en) | FULLY SPHERICAL RADIOTHERAPY SYSTEM | |
| IL285155A (en) | Metal chelator combination therapy for the treatment of cancer | |
| HUE053648T2 (hu) | Gyógyászati kombinációk rák kezelésére | |
| IL289787A (en) | Antibody combinations for treatment of cancer in specific patients | |
| EP4041064A4 (en) | A medical therapeutic device | |
| EP4122465A4 (en) | THERAPEUTIC AGENT AGAINST BREAST CANCER | |
| EP4225129A4 (en) | OCT GUIDED THERAPY | |
| EP4401721A4 (en) | CANCER TREATMENT | |
| EP4025203A4 (en) | CANCER TREATMENT | |
| IL312249A (en) | Combination therapy for treating lung cancer | |
| EP4291301C0 (en) | NON-INVASIVE CANCER TREATMENT | |
| EP4405465A4 (en) | TREATMENT METHODS | |
| EP4200012A4 (en) | Interstitial photodynamic therapy | |
| EP4188431A4 (en) | Combination therapy for cancer | |
| EP4166147A4 (en) | Sensitiser for cancer treatment |